What happens when you combine a decade of science, a powerful entrepreneurial story, and two exponential waves—AI and digital biology?You get Geneoscopy.On the latest episode of The Scope Forward Show, I caught up with Dr. Erica Barnell—Co-founder and Chief Science Officer of Geneoscopy. If you don’t know Erica yet, you should. She and her team just raised $112 million in a tough VC environment. Their lead assay, ColoSense, is now the first FDA-approved, RNA-based, non-invasive diagnostic test for colorectal cancer and advanced adenomas.But this conversation went far beyond funding and FDA milestones.We talked about:How AI has replaced costly bioinformatics layers and transformed their R&DHow patients are being guided through diagnostics via smart automation (text, email, even Uber Health)What’s next in IBD precision diagnostics and biomarker innovationWhy AI is not “artificial” at all—and how to use it without fearWhy GI, like OB/GYN, is primed for disruptionThis wasn’t just a company update—it was a glimpse into the future of our entire field.We’re in a convergence era. Biology is becoming programmable. Intelligence is being digitized. And GI—if we lean in—has a front-row seat to reinvent itself.